ArticlePloS one2020
C-reactive protein and risk of cognitive decline: The REGARDS study.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 64 citations in OpenAlex.
- Long-Term Association of Cardiovascular Risk Burden With Dementia Risk: The Role of Life-Course Confounders in an Analysis of Cumulative and Specific Factors.Journal of the American Heart Association · 2026Article
- Blood mitochondrial heteroplasmic variants and cognitive performance in late midlife: REGARDS study.BMC neurology · 2026Article
- DNA Methylation Signatures of Systemic Inflammation Are Associated With Brain Volume, Cognitive Trajectories, and Long-Term Dementia Risk.Aging cell · 2025Article
- Inflammation and Cognitive Decline: A Population-Based Cohort Study Among Aging Adults With Atrial Fibrillation.Journal of the American Heart Association · 2025Article
- Serum GFAP as a Potential Biomarker for Chemotherapy-Associated Cognitive Impairment in Elderly Patients with Gastrointestinal Cancers: An Exploratory Study.Journal of gastrointestinal cancer · 2025Observational
- Article
- Article
- Analysis and interpretation of inflammatory fluid markers in Alzheimer's disease: a roadmap for standardization.Journal of neuroinflammation · 2025Review
- Construction and evaluation of nomogram for risk prediction of cognitive impairment in chronic obstructive pulmonary disease comorbidity.BMC psychology · 2025Article
- Individual and integrated indexes of inflammation predicting the risks of mental disorders - statistical analysis and artificial neural network.BMC psychiatry · 2025Article
- Interaction and overall effects of underweight, low muscle mass, malnutrition, and inflammation on early-onset mild cognitive impairment in type 2 diabetes.Frontiers in aging neuroscience · 2025Article
- Physical capacity is associated with attention but not with general executive function in middle aged adults.PloS one · 2025Article
- The mediating role of systemic inflammation and moderating role of racialization in disparities in incident dementia.Communications medicine · 2024Article
- Exercise to Mitigate Cerebrovascular Aging: A Geroscience Perspective.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Review
- Inflammatory Markers Associated with Physical Frailty and Cognitive Impairment.Aging and disease · 2024Review
- The mediation roles of intermuscular fat and inflammation in muscle mitochondrial associations with cognition and mobility.Journal of cachexia, sarcopenia and muscle · 2024Article
- Potential biomarkers for cerebral small vessel disease with cognitive impairment: a systematic review and meta-analysis.Frontiers in aging neuroscience · 2024Review
- The role of caregiving in cognitive function and change: The REGARDS study.Psychology and aging · 2023Article
- Longitudinal associations of anticholinergic medications on cognition and possible mitigating role of physical activity.Journal of the American Geriatrics Society · 2023Article
- High-Sensitivity C-Reactive Protein, Its Change, and Cognitive Function: A National Population-Based Cohort Study.Brain sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
Markers of systemic inflammation are associated with increased risk of cognitive impairment, but it is unclear if they are associated with a faster rate of cognitive decline and whether this relationship differs by race. Our objective was to examine the association of baseline C-reaction protein (CRP) with cognitive decline among a large racially diverse cohort of older adults. Participants included 21,782 adults aged 45 and older (36% were Black, Mean age at baseline 64) from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. CRP was measured at baseline and used as a continuous variable or a dichotomous grouping based on race-specific 90th percentile cutoffs. Cognitive measures of memory and verbal fluency were administered every 2 years for up to 12 years. Latent growth curve models evaluated the association of CRP on cognitive trajectories, adjusting for relevant demographic and health factors. We found that higher CRP was associated with worse memory (B = -.039, 95% CI [-.065,-.014]) and verbal fluency at baseline (B = -.195, 95% CI [-.219,-.170]), but not with rate of cognitive decline. After covariate adjustment, the association of CRP on memory was attenuated (B = -.005, 95% CI [-.031,-.021]). The association with verbal fluency at baseline, but not over time, remained (B = -.042, 95% CI [-.067,-.017]). Race did not modify the association between CRP and cognition. Findings suggest that levels of CRP at age 45+, are a marker of cognitive impairment but may not be suitable for risk prediction for cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.